Medical Condition News

RSS

Abbott’s mental health plan draws support and surprise

The mental health proposals by Tony Abbott may have been deemed fiscally irresponsible by the federal government but they have won backing from experts of the Australian Medical Association.

25 Apr 2011

A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV).

25 Apr 2011

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology.

25 Apr 2011

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.

25 Apr 2011

Adults with PTSD and history of childhood trauma have shorter telomeres

Adults with post-traumatic stress disorder and a history of childhood trauma had significantly shorter telomere length than those with PTSD but without childhood trauma, in a study by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

25 Apr 2011

Simple, obvious and obscure ways to keep minds sharp and brains healthy

From a glance at the magazine stands, Americans appear obsessed with losing weight, cutting their cardiac risks and seeking to improve their odds against cancer. But where's the focus on brain health?

25 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Enrollment commences in Gore Early TIPS study for ascites at Indiana University Hospital

W. L. Gore & Associates today reported the first patient enrolled in the Gore Early TIPS for Ascites Study. The patient was treated at Indiana University Hospital in Indianapolis, Ind.

25 Apr 2011

Cambridge Heart releases new MTWA software

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced the release of its redesigned Microvolt T-Wave Alternans software for its HearTwave II and CH2000 platforms.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Uroplasty to present Urgent PC, Macroplastique products study data at upcoming meetings

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent PC Neuromodulation System and Macroplastique urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.

25 Apr 2011

STAA receives CE Mark approval for Visian Implantable Collamer Lens V4 design

STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive ophthalmic lenses for refractive surgery, today announced CE Mark approval for its Visian Implantable Collamer Lens V4c design.

25 Apr 2011

NCM, National Park Foundation partner to combat childhood obesity

The National Children's Museum announces that it has partnered with the National Park Foundation, the official charity of America's national parks, to support the 2011 White House Easter Egg Roll.

25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

VDF seeks nominations for PAD and venous disease research awards

The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.

25 Apr 2011

Individuals on SSRIs still exhibit depressive symptoms

Even people who show a clear treatment response with antidepressant medications continue to experience symptoms like insomnia, sadness and decreased concentration, researchers at UT Southwestern Medical Center have found after analyzing data from the largest study on the treatment of depression.

25 Apr 2011

New research provides insight into mechanism behind cardiac development

During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.

25 Apr 2011

Medical Condition News

Abbott’s mental health plan draws support and surprise

A.P. Pharma targets resubmission of APF530 NDA in 2012

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

Adults with PTSD and history of childhood trauma have shorter telomeres

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Nausea and vomiting are most feared of all chemotherapy-related side effects

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Simple, obvious and obscure ways to keep minds sharp and brains healthy

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

Enrollment commences in Gore Early TIPS study for ascites at Indiana University Hospital

Cambridge Heart releases new MTWA software

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Uroplasty to present Urgent PC, Macroplastique products study data at upcoming meetings

STAA receives CE Mark approval for Visian Implantable Collamer Lens V4 design

NCM, National Park Foundation partner to combat childhood obesity

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

VDF seeks nominations for PAD and venous disease research awards

Individuals on SSRIs still exhibit depressive symptoms

New research provides insight into mechanism behind cardiac development

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News